The prognostic impact of shocks for clinical and induced arrhythmias on morbidity and mortality among patients with implantable cardioverter-defibrillators

Heart Rhythm

Volumn 7, Issue 6, 2010, Pages 755-760

  Bhavnani, Sanjeev P ^a   Kluger, Jeffrey ^a   Coleman, Craig I ^a   White, C Michael ^a   Guertin, Danette ^a   Shafi, Nabil A ^a   Yarlagadda, Ravi K ^a   Clyne, Christopher A ^a  

^a Evidence Based Practice Center   (United States)

Author keywords

Defibrillator; Morbidity; Mortality; Risk factors; Shocks

Indexed keywords

ACUTE DECOMPENSATED HEART FAILURE; ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DEFIBRILLATOR; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ELECTROPHYSIOLOGY; HEART FUNCTION TEST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK; SECONDARY PREVENTION; SUDDEN DEATH;

AGED; ANTI-ARRHYTHMIA AGENTS; COHORT STUDIES; CONFIDENCE INTERVALS; CONNECTICUT; DEFIBRILLATORS, IMPLANTABLE; DIGOXIN; ELECTROPHYSIOLOGY; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; PHENETHYLAMINES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONAMIDES; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 77952529329     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2010.02.039     Document Type: Article

References (25)

1. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 3 (2005) 225-237
2. The Antiarrhythmic versus Implantable Cardioverter Defibrillators Investigators. A comparison of antiarrhythmic-drug therapy with implantable cardioverter defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337 (1997) 1576-1583
3. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
4. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
5. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350:2151-2158.
6. Poole J.E., Johnson G.W., Hellkamp A.S., et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 359 (2008) 1009-1017
7. Daubert J.P., Zareba W., Cannom D.S., et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 51 (2008) 1357-1365
8. Schron E.B., Exner D.V., Yao Q., et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 105 (2002) 589-594
9. Van den Broek K.C., Nyklícek I., Van der Voort P.H., Alings M., and Denollet J. Shocks, personality, and anxiety in patients with an implantable defibrillator. Pacing Clin Electrophysiol 31 (2008) 850-857
10. Hurst T., Hinrichs M., Breidenbach C., Katz N., and Waldecker B. Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. J Am Coll Cardiol 34 (1999) 402-408
11. Germano J.J., Reynolds M., Essebag V., and Josephson M.E. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic?. Am J Cardiol 97 (2006) 1255-1261
12. von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P., and STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Ann Intern Med 147 (2007) 573-577
13. Moss A.J., Greenberg H., Case R.B., et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 110 (2004) 3760-3765
14. Saxon L.A., Bristow M.R., Boehmer J., et al. Predictors of sudden cardiac death and appropriate shock in the COMPANION trial. Circulation 114 (2006) 2766-2772
15. Klein R.C., Raitt M.H., Wilkoff B.L., et al. Analysis of implantable cardioverter defibrillator therapy in the AVID trial. J Cardiovasc Electrophysiol 9 (2003) 940-948
16. Anastasiou-Nana M.I., Tsagalou E.P., Charitos C., et al. Effects of transient myocardial ischemia on the ventricular defibrillation threshold. Pacing Clin Electrophysiol 28 (2005) 97-101
17. Ouyang P., Brinker J.A., Bulkley B.H., Jugdutt B.I., and Varghese P.J. Ischemic ventricular fibrillation: The importance of being spontaneous. Am J Cardiol 48 (1981) 455-459
18. Kalus J.S., White C.M., Caron M.F., Guertin D., McBride B.F., and Kluger J. The impact of catecholamines on defibrillation threshold in patients with implanted cardioverter defibrillators. Pacing Clin Electrophysiol 28 (2005) 1147-1156
19. Sims J.J., Miller A.W., and Ujhelyi M.R. Regional hyperkalemia increases ventricular defibrillation energy requirements: Role of electrical heterogeneity in defibrillation. J Cardiovasc Electrophysiol 11 (2000) 634-641
20. Martin D.J., Chen P.S., Hwang C., et al. Upper limit of vulnerability predicts chronic defibrillation threshold for transvenous implantable defibrillators. J Cardiovasc Electrophysiol 8 (1997) 241-248
21. Gold M.R., Higgins S., Klein R., et al. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation. Circulation 105 (2002) 2043-2048
22. Pires L.A., and Johnson K.M. Intraoperative testing of the implantable cardioverter-defibrillator: How much is enough?. J Cardiovasc Electrophysiol 17 (2006) 140-145
23. Whang W., Mittleman M.A., Rich D.Q., et al. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the TOVA study. Circulation 109 (2004) 1386-1391
24. Goldenberg I., Moss A.J., Hall W.J., et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 113 (2006) 2810-2817
25. Pietrasik G., Goldenberg I., McNitt S., Polonsky B., Moss A.J., and Zareba W. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators. J Cardiovasc Electrophysiol 20 (2009) 395-400